Filtered By:
Therapy: Hormonal Therapy

This page shows you your search results in order of date. This is page number 15.

Order by Relevance | Date

Total 218 results found since Jan 2013.

While hormone therapy unlikely harmful in younger postmenopausal women at low CV risk, protective effects cannot be claimed
Commentary on: Schierbeck LL, Rejnmark L, Tofteng CL, et al.. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012;345:e6409. Context The last 10 years have clarified the issues regarding postmenopausal hormone therapy (HT) and cardiovascular disease (CVD). Prior to the large, randomised women's health initiative (WHI),1 observational studies had suggested a protective cardiovascular (CV) effect. The WHI showed no benefit, and increased thromboembolic and CV events in women taking HT. The WHI findings have been challenged because of the older age of the...
Source: Evidence-Based Medicine - September 19, 2013 Category: Internal Medicine Authors: Abramson, B. L. Tags: Epidemiologic studies, Drugs: cardiovascular system, Stroke, Menopause (including HRT), Ischaemic heart disease, Venous thromboembolism Therapeutics Source Type: research

Study: Different hormone therapy formulations may pose different risks for heart attack and stroke
(Cedars-Sinai Medical Center) Post-menopausal women whose doctors prescribe hormone replacement therapy for severe hot flashes and other menopause symptoms may want to consider taking low doses of FDA-approved bioidentical forms of estrogen or getting their hormones via a transdermal patch. A new observational study shows bioidentical hormones in transdermal patches may be associated with a lower risk of heart attack and FDA-approved products -- not compounded hormones -- may be associated with a slightly lower risk of stroke compared to synthetic hormones in pill form.
Source: EurekAlert! - Medicine and Health - September 18, 2013 Category: Global & Universal Source Type: news

Higher parity is associated with an increased risk of type‐II diabetes in Chinese women: the Singapore Chinese Health Study
ConclusionsIncreased parity may be a risk factor for type‐II diabetes in Chinese women. More research is needed on lifestyle and physiologic factors that may explain this association.
Source: BJOG: An International Journal of Obstetrics and Gynaecology - June 21, 2013 Category: OBGYN Authors: NT Mueller, NJ Mueller, AO Odegaard, MD Gross, WP Koh, JM Yuan, MA Pereira Tags: Original Article Source Type: research

Hormone therapy not recommended for chronic disease prevention in menopausal women
Commentary on: Nelson HD, Walker M, Zakher B, et al.. Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the US Preventive Services Task Force recommendations. Ann Intern Med 2012;157:104–13. Context In 2005, the US Preventive Services Task Force (USPSTF) updated its 2002 hormone replacement therapy recommendations, advising against the routine use of oestrogen and progestin (E+P) and unopposed oestrogen (E) to prevent chronic conditions in menopausal women. Menopausal hormone therapy (MHT) had been commonly prescribed to prevent conditions such as cardiovascula...
Source: Evidence-Based Medicine - May 15, 2013 Category: Internal Medicine Authors: Wenger, N. K. Tags: Pancreas and biliary tract, Epidemiologic studies, Drugs: cardiovascular system, Dementia, Stroke, Contraception, Drugs: obstetrics and gynaecology, Menopause (including HRT), Ischaemic heart disease, Venous thromboembolism, Memory disorders (psychiatry), Source Type: research

A Post-Hoc Assessment of Current Hormone Therapy on Revascularization Risk in Women: The Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST) (P03.168)
CONCLUSIONS: We found that women on current HRT have lower periprocedural risk associated with CAS or CEA than non-users, but little difference in risk after the procedural period. The mechanism for this unexpected finding is elusive. We urge caution in the interpretation of this post-hoc observation and encourage replication or refutation by other revascularization studies with similar data.Disclosure: Dr. Mackey has nothing to disclose. Dr. Lutsep has received personal compensation for serving on Consultant/Advisory Boards for Concentric Medical/Stryker, Co-Axia, and AGA Medical. Dr. Lutsep has received personal compensa...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Mackey, A., Lutsep, H., Milot, G., Voeks, J., Howard, V., Hughes, S., Tom, M., Longbottom, M., Sheffet, A., Brott, T. Tags: P03 Cerebrovascular Disease III Source Type: research

Why is greater medication adherence associated with better outcomes
Background: To evaluate potential explanations for the association of greater adherence to placebo medication with better outcomes. Methods: The three explanations evaluated were that subjects with greater placebo adherence were 1) more likely to adhere to other medications, 2) had better healthcare behaviors, and 3) had lower risk. The data included more than 800 risk factors from the Women's Health Initiative (WHI), a nationwide study that included women who participated in randomized controlled trials of estrogen plus progestin (n=16,608) or estrogen alone (n=10,739). The median follow-up was 8 years. Linear regression ...
Source: Emerging Themes in Epidemiology - February 2, 2013 Category: Epidemiology Authors: Arthur HartzTao He Source Type: research

Lessons Learned From the Women's Health Initiative Trials of Menopausal Hormone Therapy.
Abstract We re-evaluate the Women's Health Initiative findings and their implications for clinical practice. Menopausal hormone therapy (HT) was effective for relief of vasomotor symptoms, and the risk of coronary heart disease (CHD) tended to be reduced in women close to menopause compared with the increased risk in women more distant from menopause. In recently menopausal women, short-term absolute risks of stroke and venous thromboembolism were small. Estrogen plus progestin therapy, but not estrogen therapy, increased the risk of breast cancer with a suggestion of greater risk when initiated close to the menop...
Source: Obstetrics and Gynecology - January 1, 2013 Category: OBGYN Authors: Rossouw JE, Manson JE, Kaunitz AM, Anderson GL Tags: Obstet Gynecol Source Type: research

Hormone therapy and the prevention of cardiovascular disease and cognitive decline: Where do we stand?
Postmenopausal hormone therapy (HT) has long been used for the treatment of menopausal symptoms and urogenital atrophy. Large epidemiological studies have indicated that HT may prevent cardiovascular disease , the Women's Health Initiative (WHI) trial, however, has demonstrated that HT is associated with an increase of cardiovascular outcomes, namely myocardial infarction and stroke . Several reasons have been proposed for this discrepancy, the most important being the old age of the participants, representing thus a population highly divergent from the young, symptomatic recently postmenopausal woman eligible for HT. Estr...
Source: Maturitas - December 6, 2012 Category: Primary Care Authors: Irene Lambrinoudaki, Faustino R. Pérez-López Tags: Editorial Source Type: research